NASDAQ:SLDBSolid Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Solid Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.07 -0.02 (-0.65 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$3.02Now: $3.07▼$3.4850-Day Range$2.10MA: $2.57▼$3.1652-Week Range$1.96Now: $3.07▼$13.58Volume513,140 shsAverage Volume385,240 shsMarket Capitalization$141.44 millionP/E RatioN/ADividend YieldN/ABeta1.14 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingSolid Biosciences has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.43, Solid Biosciences has a potential upside of 207.1% from its current price of $3.07.Amount of Analyst CoverageSolid Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesSolid Biosciences has received 215 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSolid Biosciences has received 197 “underperform” votes. (Add your “underperform” vote.)Community SentimentSolid Biosciences has received 52.18% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote “Outperform” if you believe SLDB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSolid Biosciences does not currently pay a dividend.Dividend GrowthSolid Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Solid Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 33.12% of the stock of Solid Biosciences is held by insiders.Percentage Held by Institutions42.63% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Solid Biosciences are expected to grow in the coming year, from ($1.67) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Solid Biosciences is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Solid Biosciences is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSolid Biosciences has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.50 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLDB Previous Symbol CUSIPN/A CIK1707502 Webwww.solidbio.com Phone617-337-4680Debt Debt-to-Equity Ratio0.08 Current Ratio4.50 Quick Ratio4.50Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.74 per share Price / Book1.76Profitability EPS (Most Recent Fiscal Year)($2.91) Net Income$-117,220,000.00 Net MarginsN/A Return on Equity-139.82% Return on Assets-111.10%Miscellaneous Employees111 Outstanding Shares46,071,000Market Cap$141.44 million Next Earnings Date8/12/2020 (Estimated) OptionableOptionable NASDAQ:SLDB Rates by TradingView Receive SLDB News and Ratings via Email Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions How has Solid Biosciences' stock been impacted by COVID-19 (Coronavirus)? Solid Biosciences' stock was trading at $3.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SLDB shares have decreased by 2.2% and is now trading at $3.07. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Solid Biosciences? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Solid Biosciences. When is Solid Biosciences' next earnings date? Solid Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Solid Biosciences. How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc (NASDAQ:SLDB) announced its earnings results on Thursday, March, 12th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $0.04. View Solid Biosciences' earnings history. What price target have analysts set for SLDB? 7 analysts have issued 1 year target prices for Solid Biosciences' stock. Their forecasts range from $2.00 to $22.00. On average, they anticipate Solid Biosciences' share price to reach $9.43 in the next year. This suggests a possible upside of 207.1% from the stock's current price. View analysts' price targets for Solid Biosciences. Has Solid Biosciences been receiving favorable news coverage? News coverage about SLDB stock has been trending negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Solid Biosciences earned a news impact score of -2.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutSolid Biosciences. Are investors shorting Solid Biosciences? Solid Biosciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 795,600 shares, a decrease of 18.7% from the April 30th total of 978,800 shares. Based on an average trading volume of 320,100 shares, the short-interest ratio is presently 2.5 days. Approximately 2.7% of the shares of the company are sold short. View Solid Biosciences' Current Options Chain. Who are some of Solid Biosciences' key competitors? Some companies that are related to Solid Biosciences include Innate Pharma (IPHYF), Scholar Rock (SRRK), Nantkwest (NK), Rubius Therapeutics (RUBY), Voyager Therapeutics (VYGR), DBV TECHNOLOGIE/S (DBVT), Autolus Therapeutics (AUTL), Agenus (AGEN), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Tcr2 Therapeutics (TCRR) and ADMA Biologics (ADMA). View all competitors. What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Solid Biosciences investors own include Agile Therapeutics (AGRX), Amarin (AMRN), Selecta Biosciences (SELB), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Fate Therapeutics (FATE), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Viking Therapeutics (VKTX) and Zynerba Pharmaceuticals (ZYNE). Who are Solid Biosciences' key executives? Solid Biosciences' management team includes the following people: Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48) When did Solid Biosciences IPO? (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers. What is Solid Biosciences' stock symbol? Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB." Who are Solid Biosciences' major shareholders? Solid Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (14.65%), Morgan Stanley (1.22%), State Street Corp (0.78%), Geode Capital Management LLC (0.64%), JPMorgan Chase & Co. (0.59%) and Deutsche Bank AG (0.28%). Company insiders that own Solid Biosciences stock include Boxer Capital, Llc, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View institutional ownership trends for Solid Biosciences. Which major investors are selling Solid Biosciences stock? SLDB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Spark Investment Management LLC, Deutsche Bank AG, and UBS Group AG. View insider buying and selling activity for Solid Biosciences. Which major investors are buying Solid Biosciences stock? SLDB stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, JPMorgan Chase & Co., Two Sigma Advisers LP, Wells Fargo & Company MN, Raymond James Financial Services Advisors Inc., Voloridge Investment Management LLC, Geode Capital Management LLC, and GSA Capital Partners LLP. View insider buying and selling activity for Solid Biosciences. How do I buy shares of Solid Biosciences? Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Solid Biosciences' stock price today? One share of SLDB stock can currently be purchased for approximately $3.07. How big of a company is Solid Biosciences? Solid Biosciences has a market capitalization of $141.44 million. The company earns $-117,220,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe. What is Solid Biosciences' official website? The official website for Solid Biosciences is www.solidbio.com. How can I contact Solid Biosciences? Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680. This page was last updated on 5/26/2020 by MarketBeat.com Staff
